Phototherapy for atopic dermatitis: Systematic review and network meta-analysis of randomized controlled trials.
Photodermatol Photoimmunol Photomed
; 38(3): 233-240, 2022 May.
Article
em En
| MEDLINE
| ID: mdl-34653289
ABSTRACT
BACKGROUND:
Phototherapies could represent an efficient option for the treatment of atopic dermatitis (AD), but the evidences available for clinical choices were contradictory.OBJECTIVE:
This study aimed to evaluate the efficacy of different phototherapies on AD.METHODS:
This systematic review and network meta-analysis included randomized controlled trials (RCTs) through searching keywords from PubMed, EMBASE, and the Cochrane library. We summarized different phototherapy types and scoring systems. Scoring Atopic Dermatitis (SCORAD) absolute score changes were estimated by mean differences (MDs) and standard deviations (SDs) and then included in the network meta-analysis. The effect sizes of comparison of different phototherapies were presented as MDs and 95% confidence intervals (CIs). Egger's test was used to evaluate publication bias.RESULTS:
Eleven RCTs were included in the systematic review and 4 studies in the network meta-analysis. Based on the pooled estimates, medium-dose ultraviolet A1 (UVA1) cold light was superior to medium-dose UVA1 (MD 8.92; 95% CI 5.60-12.24) but no significant difference between high-dose (UVA1) and medium-dose UVA1 cold light (MD 0.66; 95% CI -5.57 to 6.90). Publication bias was not supported by Egger's test (P = .168).CONCLUSIONS:
Due to possible long-term adverse effects of high-dose UVA1, medium-dose UVA1 cold light appears to be the superior form for AD.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Terapia Ultravioleta
/
Dermatite Atópica
Tipo de estudo:
Clinical_trials
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Photodermatol Photoimmunol Photomed
Ano de publicação:
2022
Tipo de documento:
Article